Cortical laminar distribution of β-amyloid deposits in five neurodegenerative disorders

Richard A. Armstrong
Vision Sciences, Aston University, Birmingham, United Kingdom

Folia Neuropathol 2020; 58 (1): 1-9 DOI: https://doi.org/10.5114/fn.2020.94001

Abstract

Alzheimer's disease neuropathologic change (ADNC) in the form of β-amyloid (Aβ) deposits occurs not only in Alzheimer's disease (AD) and Down's syndrome (DS) but also as a ‘co-pathology’ in several disorders including dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE). To determine whether cortical laminar degeneration, as measured by Aβ deposition, is similar in different disorders, changes in density of the diffuse, primitive, and classic morphological subtypes of Aβ deposit were studied across all cortical layers in the frontal and temporal cortex in AD, DS, DLB, CBD, and CTE using quantitative analysis and polynomial curve fitting. In AD, CTE, and DLB, the diffuse Aβ deposits were distributed most frequently in the upper cortical layers, distribution being more variable in DS and CBD. In all disorders, the primitive Aβ deposits were distributed primarily in the upper layers, but in DLB, a bimodal distribution with peaks of density in upper and lower layers was evident in some gyri. The distribution of the classic deposits varied both within and among disorders. The many similarities in laminar distribution among disorders suggest common patterns of cortical degeneration. Where differences occur, they may reflect variations in the ‘prion-like’ propagation of Aβ along anatomical pathways in the different disorders.

Key words: Alzheimer’s disease neuropathologic change (ADNC), β-amyloid (Aβ), cortical laminar distribution, neurodegenerative disorders, cortical degeneration.

Introduction

Alzheimer's disease neuropathologic change (ADNC) in the form of β-amyloid (Aβ) deposits occurs in a variety of neuropathological settings [43,56]. Hence, Aβ is a ‘signature’ pathological lesion of Alzheimer’s disease (AD) [45,55] and also plays a significant role in the pathology of Down’s syndrome (DS) [12,31,48,57]. In addition, Aβ deposits have been reported as a ‘co-pathology’ in many neurodegenerative disorders including in some cases of dementia with Lewy bodies (DLB) [14], Parkinson’s disease (PD) [59], Pick’s disease (PiD) [59], corticobasal degeneration (CBD) [6,59], amyotrophic lateral sclerosis (ALS) [36], progressive supranuclear palsy (PSP) [59], and chronic traumatic encephalopathy (CTE) [66].

Aβ peptides are generated in brain by β- and γ-secretase cleaving of amyloid precursor protein (APP), resulting in the formation of aggregated protein deposits [35,40]. A number of morphological types of Aβ deposit have been described in historical sections in AD and DS, but the majority can...
be classified into three subtypes [3,26]. First, diffuse ('pre-amyloid') deposits are closely associated with neuronal cell bodies, and may be the earliest type to develop [1,3,4]. Second, primitive ('neuritic') deposits are more mature deposits which incorporate dystrophic neurites (DN) [3]. Third, classic ('dense-cored') Aβ deposits consist of a distinct central 'core' surrounded by a 'corona' of DN and are frequently located adjacent to prominent blood vessels [5]. In AD, all three types of Aβ deposit are distributed unevenly across the cortex with peaks of density in different cortical layers, the primitive and classic Aβ deposits often reaching maximum density in the upper and lower layers respectively while the diffuse deposits have a more variable distribution [2,8].

A previous study [10] investigated the spatial patterns of Aβ deposits in the upper cortex parallel to the pia mater and found considerable similarities in their pattern of clustering in different disorders. The laminar distribution of Aβ deposits may indicate the pattern of degeneration across the cortical layers and has been studied quantitatively in AD [2,8]. The specific objective of this study was to directly compare laminar distributions of Aβ deposits in five neurodegenerative disorders including not only AD but also CBD, DLB, DS, and CTE which have been less studied quantitatively to determine whether there were differences associated with variations in the clinical and pathological setting. Hence, AD, CBD, and CTE are 'tauopathies' [32] in which the deposition of abnormal forms of the microtubule-associated protein (MAP) tau in the form of neurofibrillary tangles (NFT), glial inclusions (GI), and dot-like grains (DLG) is a 'signature' pathological feature [47]. By contrast, DLB is a 'synucleinopathy' in which the misfolded forms of the synaptic protein α-synuclein are deposited as Lewy bodies (LB), Lewy neurites (LN), and Lewy grains (LG) [32,65]. In DS, increased Aβ deposition may result from triplication of the APP gene [60], while in CTE, Aβ deposition may be a consequence of traumatic brain injury (TBI) [30,44,50,66].

Material and methods

Cases

Demographic data and diagnostic criteria for the five disorders are listed in Table I [54,55,68]. Informed consent was given for the removal of all brain tissue according to the 1996 Declaration of Helsinki (as modified Edinburgh 2000). Case material for AD, CBD, DLB, and DS, in the form of original microscope slides, was obtained from the Brain Bank, Department of Neuropathology, Institute of Psychiatry, King’s College, London, UK. By contrast, because of its scarcity, case material for CTE was obtained from Boston University’s CTE Center (VA-BU-CLF Brain Bank) as a series of scanned microscope images (Aperio Image-Scope Software, Leica Biosystems Inc. Buffalo Grove, IL, USA) [17,18]. To check whether determination of laminar distribution was affected by observation of scanned images rather than the original slides, a random sample of regions from the AD cases was also studied both from microscope slides and from scanned images, no differences in distribution being detected.

Histological methods

Blocks of frontal cortex, at the level of the genu of corpus callosum and temporal cortex, at the level of the lateral geniculate nucleus, were taken from

| Disorder | N | Mean age (SD) | M : F | Signature lesion | Additional pathology | Diagnostic criteria |
|----------|---|---------------|------|-----------------|----------------------|---------------------|
| AD       | 10 | 78.2 (8.3)    | 3 : 7 | Aβ deposits     | EN, GVC, NFT         | NINCDS/ADRDA/CERAD  |
| CBD      | 4  | 62.5 (8.01)   | 2 : 2 | NFT             | AR, GI, EN           | NIH-ORD             |
| CTE      | 6  | 71.6 (8.2)    | 6 : 0 | NFT             | DN, DLG              | McKee et al. [53]   |
| DLB      | 8  | 71.5 (3.40)   | 8 : 0 | LB              | LN, LG               | CDLB                |
| DS       | 11 | 40.7 (4.03)   | 6 : 5 | Aβ deposits     | NFT                  | By karyotype        |

AD – Alzheimer’s disease, CBD – corticobasal degeneration, CTE – chronic traumatic encephalopathy, DLB – dementia with Lewy bodies, DS – Down’s syndrome, AP – astrocytic plaques, DN – dystrophic neurites, DLG – dot-like grains, EN – enlarged neurons, GVC – granulovacuolar change, LB – Lewy bodies, LG – Lewy grains, LN – Lewy neurites, NFT – neurofibrillary tangles, NINCDS/ADRDA – National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association [58], CERAD criteria – Consortium to Establish a Registry of Alzheimer Disease [55], NIH-ORD – National Institute of Health-Office of rare disorders, CDLB – Consortium on Dementia with Lewy bodies [54], N – number of cases studied, M – male, F – female, SD – standard deviation.
each case to study the superior frontal gyrus (SFG) (B8), lateral-occipito temporal gyrus (LOT) (B36), and parahippocampal gyrus (PHG) (B28), gyri which frequently have high densities of Aβ deposits in AD and related disorders [2,6,12,14]. Tissue was fixed in 10% phosphate buffered formal saline and embedded in paraffin wax. 7 µm coronal sections were stained with rabbit polyclonal antibodies raised against Aβ42 [64,66]. Sections were also stained with hematoxylin. The antibodies clearly revealed the diffuse, primitive, and classic subtypes of Aβ deposit and were identified in the sections using previously defined criteria [3,26] (Fig. 1). Hence, diffuse Aβ deposits were 10-200 µm in diameter, irregular in shape with diffuse boundaries, and were lightly immunolabelled. Primitive Aβ deposits were 20-60 µm in diameter, well demarcated, more symmetrical in shape, and strongly immunolabelled, while the classic Aβ deposits were 20-100 µm, comprising a distinct and strongly immunolabelled central ‘core’ surrounded by a ‘corona’ of DN.

**Morphometric methods**

The laminar distribution of the Aβ deposits in each gyrus was studied using methods described previously [8,28]. Hence, five traverses extending from the pia mater to the edge of the white matter were located at random locations along each gyrus where significant densities of Aβ deposits were present. All diffuse, primitive, and classic Aβ deposits were counted in 200 × 1000 µm sample fields arranged contiguously along the traverse, the larger dimension of the field orientated parallel with the surface of the pia mater. In AD, CBD, DLB, and DS, an eye-piece micrometer was used as the sample field and was moved down each traverse one step at a time from the pia mater to the edge of the white matter. In CTE, the sample fields were superimposed over the scanned images using either the draw or rectangle options [17,18]. Histological features of the section were used to correctly position the field. The mean of the counts from the five traverses was calculated to study variations in density of histological features across each cortical gyrus.

**Data analysis**

The degree of cortical degeneration present in many gyri, especially in AD and CTE, made laminar identification difficult especially in the SFG in all disorders because it exhibits a heterotypical structure, i.e., six layers cannot always be clearly identified and vary in prominence from case to case [8]. In addition, Aβ deposits appeared to exhibit complex patterns of distribution across the cortex rather than being confined to individual layers. Instead, variations in density of Aβ deposits with distance across the cortex were analyzed using a polynomial curve-fitting procedure (STATISTICA software, StatSoft Inc., 2300 East 14th St, Tulsa, OK, 74104, USA) [2,63]. For each gyrus, polynomials of order 1, 2, 3 up to the 4th order were fitted successively to the data. With each fitted polynomial, the correlation coefficients (Pearson’s r), regression coefficients (β), standard errors (SE), values of t, and the residual mean square (MS) were obtained. A polynomial was accepted as the ‘best’ fit when either a non-significant value of F was obtained for the next higher order polynomial or there was little gain in explained variance [58]. As a large number of statistical tests were performed without pre-planned hypotheses, the Bonferroni correction was applied to each set of comparisons, i.e., among deposit types within a disorder, among disorders, and among individual disorders for each type of deposit [7]. Where significant changes in density occurred across the cortex, the analyses were used to establish the approximate location of any significant peaks. In the majority of gyri, there was either a single density peak in the upper or lower cortex (unimodal distribution), corresponding to layers I

![Fig. 1. The three morphological subtypes of β-amyloid (Aβ) deposits observed in a case of chronic traumatic encephalopathy (CTE): (A) diffuse (D), (B) primitive (P), (C) classic deposit (CL) (Aβ42 Immunostaining, H/E, bar = 100 µm).](image-url)
or V/VI respectively, or two peaks in the upper and lower cortex (bimodal distribution).

**Results**

Examples of the laminar distributions of Aβ deposits observed are shown in Figures 2 and 3. Figure 2 shows the distribution of Aβ deposits in the LOT of a case of CTE located primarily in the upper cortex and associated with many Aβ-immunolabelled cell bodies. By contrast, Figure 3 shows the distribution of Aβ deposits in the SFG of a case of DLB affecting the lower layers with only a few scattered diffuse deposits in the upper layers.

Examples of the polynomial curve fitting procedure in the SFG of a case of AD are shown in Figure 4. The distribution of the diffuse Aβ deposits was fitted by a third-order polynomial \( r = 0.70, p < 0.05 \), suggesting a bimodal distribution, high densities being present in the superficial layers and a density peak in the lower cortex. By contrast, the primitive Aβ deposits were fitted by a first-order linear regression \( r = 0.82, p < 0.01 \), with the highest density of deposits in the upper cortex, and with a linear decline in density across the cortex. The classic Aβ deposits were fitted best by a third-order polynomial \( r = 0.64, p < 0.05 \), and although there was less change in density compared with the diffuse and primitive deposits, the greatest densities were present in the upper cortex.

A summary of the frequencies of the different types of laminar distribution of the diffuse, primi-
Table II. Cortical laminar distributions of the diffuse, primitive, and classic β-amyloid (Aβ) deposits in five neurodegenerative disorders

| Disorder | Aβ deposit subtype | N | Upper cortex | Lower cortex | Bimodal | NS |
|----------|-------------------|---|--------------|--------------|---------|----|
| AD       | Diffuse           | 33 | 14           | 5            | 4       | 10 |
|          | Primitive         | 33 | 28           | 0            | 3       | 2  |
|          | Classic           | 32 | 8            | 7            | 8       | 9  |
| CBD      | Diffuse           | 6  | 1            | 2            | 2       | 1  |
|          | Primitive         | 6  | 5            | 1            | 0       | 0  |
|          | Classic           | 6  | 2            | 0            | 2       | 2  |
| CTE      | Diffuse           | 25 | 10           | 2            | 5       | 8  |
|          | Primitive         | 23 | 9            | 1            | 1       | 12 |
|          | Classic           | 20 | 3            | 4            | 1       | 12 |
| DLB      | Diffuse           | 17 | 11           | 1            | 5       | 0  |
|          | Primitive         | 17 | 9            | 1            | 7       | 0  |
|          | Classic           | 10 | 1            | 2            | 5       | 2  |
| DS       | Diffuse           | 16 | 5            | 8            | 2       | 1  |
|          | Primitive         | 14 | 9            | 2            | 2       | 1  |
|          | Classic           | 8  | 5            | 1            | 1       | 1  |

AD – Alzheimer’s disease, CBD – corticobasal degeneration, CTE – chronic Traumatic encephalopathy, DLB – dementia with Lewy bodies, DS – Down’s syndrome, N – number of gyri studied, NS – no significant change in density across the cortex.

Comparison of spatial patterns ($\chi^2$ contingency tables). *Comparisons significant after Bonferroni correction:

(1) Among deposit types within each disorder:
- $\chi^2 = 27.35$ (6 DF, $p < 0.001$), DS $\chi^2 = 6.48$ (6 DF, $p > 0.05$), DLB $\chi^2 = 13.37$ (6 DF, $p < 0.05$), CBD $\chi^2 = 9.25$ (6 DF, $p > 0.05$), CTE $\chi^2 = 11.05$ (6 DF, $p > 0.05$)

(2) Among all disorders:
- $\chi^2 = 21.96$ (12 DF, $p < 0.05$), Class deposits $\chi^2 = 21.96$ (12 DF, $p < 0.05$)

(3) Among individual disorders:
- Diffuse deposits $\chi^2 = 32.40$ (12 DF, $p < 0.001$), Primitive deposits $\chi^2 = 16.73$ (12 DF, $p > 0.05$), Classic deposits $\chi^2 = 21.96$ (12 DF, $p < 0.05$)

Discussion

Laminar distributions are similar to those reported previously with regard to Aβ deposits in sporadic [2]...
and familial AD [8] and in other studies of AD reporting high densities of silver-stained senile plaques (SP) in the upper cortical layers [22,23,28,38]. Few studies have been carried out on the laminar distribution of Aβ deposits in disorders other than AD, but the tau-immunoreactive pathology in CBD [15] and in CTE [19] is frequently distributed primarily in the upper cortex. By contrast, DLB is an exception in that LB pathology often exhibits a bimodal distribution but with higher densities in the lower cortex [13].

The density peak of the diffuse Aβ deposits in the upper cortical layers could result from the spatial association of these deposits with large neuronal perikarya [1,4]. These deposits may represent an early stage in degeneration of the large pyramidal cells in the upper cortex, many of which are the cells of origin of the feed-forward cortico-cortical pathways (FF-CC) [3]. Similarly, the primitive Aβ deposits commonly exhibit a density peak in the upper cortex and may result from the maturation of diffuse deposits [3] and also suggest degeneration of the FF-CC [2,24,38] in all five disorders. Third, the classic ‘cored’ deposits occur most frequently in the lower layers in AD [2,21], but the present study reveals a more variable distribution which could result from the relationship between the classic Aβ deposits and cerebral blood vessels [5].

Aβ deposits were more likely to be distributed across all cortical layers in AD and especially in CTE. AD and CTE are both tauopathies, but CTE is associated specifically with TBI [30,34,44,51-53,62] while the cause of sporadic AD is likely to be more complex [11], identifying this disorder as having the most widespread laminar degeneration among those studied. The distribution of the classic Aβ deposits may be of particular significance in CTE as it could reflect blood vessel damage [5]. Hence, the tau-immunoreactive pathology in CTE occurs at higher density in sulci compared with gyri, where blood vessels are densest [17,46,52], accompanied by a marked perivascular distribution of NFT and AT [51,53]. The remaining tauopathy CBD exhibits a laminar distribution which closely resembles that of AD, which could explain why the diagnosis of CBD is difficult, diverse presentations being present and frequently resembling other disorders such as AD [27]. DS and AD share many pathological similarities [48,57,69], particular accumulations of Aβ deposits being observed between the ages of 30 and 50 years [42] and this study confirms the considerable similarity in their laminar distributions. The synucleinopathy DLB exhibits some differences compared with the other disorders, and especially CTE, in the frequency of bimodal distribution of the primitive deposits, and which could be the result of two pathological processes, viz. neuronal degeneration affecting the lower layers associated with α-synuclein-mediated LB formation [13] and degeneration affecting the upper layers.

Variation in laminar distribution could represent different stages in a dynamic process reflecting the hypothesized ‘prion-like’ spread of Aβ among regions via neuro-anatomical pathways [9,33,67]. The observation that Aβ deposits in AD exhibit very similar spatial patterns in the tissue to PrPsc deposits in Creutzfeldt-Jakob disease (CJD) supports this hypothesis [16]. The following hypothesis is suggested to account for the observed laminar distributions. First, messenger RNA (mRNA) of amyloid precursor protein (APP) is preferentially expressed by the large pyramidal neurons [20]. Degeneration of these neurons, initially in layer III, results in increased secretion of APP and formation of diffuse Aβ deposits in association with one or more neurons [4]. Second, interleukin-immunoreactive microglia (IL-Mg) have a similar laminar distribution to APP-immunoreactive neuritic plaques (NP) and contribute to the maturation of Aβ to form the primitive Aβ deposits [61]. Degeneration of blood vessels may be an additional factor involved in the formation of the cored classic deposits [5]. Third, Aβ spreads via local interneurons from upper to lower layers to gradually affect all cortical layers, a process evident in AD and most especially in CTE. Release of APP and maturation into amyloid associated with neurons in layer V may also contribute to this spread in AD and CTE. Fourth, further spread of Aβ occurs among cortical gyri via pathways including the short and long cortico-cortical pathways [24].

NFT also occur in greater abundance in the upper cortical layers in AD [38]. Whether there is a direct link between the laminar distribution of Aβ deposits and that of NFT, as suggested in AD by the amyloid cascade hypothesis (ACH), is unclear [37]. SP and NFT can develop alone in different disorders, e.g., NFT in tangle-only dementia [70] and Aβ in hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHA-D) [41]. SP and NFT may exhibit distinct but independently distributed topographic patterns in the cerebral cortex in AD [41]. In addition, Braak and
Braak [23] showed that tau pathology occurred first in the entorhinal cortex, often in the absence of SP, whereas the subsequent spread and distribution of Aβ was more variable. Moreover, SP and NFT may be temporally separated in the brain [49], NFT preceding the appearance of SP in some regions. Nevertheless, it is also possible that Aβ and tau formation are different consequences of degeneration of the same neurons, SP forming on the axonal terminals of NFT-containing neurons, and the respective laminar distributions of the SP and NFT may reflect this anatomical association [24].

In conclusion, cortical laminar distributions of Aβ deposits in AD, CBD, CTE, DLB, and DS show considerable similarities and some differences. Differences among individual cases and disorders could reflect variations in the pathological spread of Aβ among brain regions via anatomical pathways and may play a significant role in the timing and sequence of clinical symptoms exhibited by the patient.

Acknowledgements

The assistance of the Brain Bank, Institute of Psychiatry, King’s College London, UK and Boston University Alzheimer’s Disease Center CTE Program Brain Bank, Boston University School of Medicine, Boston, MA, USA in supplying case material for this study are gratefully acknowledged.

Disclosure

The author reports no conflict of interest.

References

1. Allsop D, Haga S, Ikeda S, Mann DMA, Ishii T. Early senile deposits in Down’s syndrome brains show a close relationship with cell bodies of neurons. Neuropathol Appl Neurobiol 1989; 15: 531-542.
2. Armstrong RA. β-amyloid (Aβ) deposits and blood vessels: laminar distribution in the frontal cortex of patients with Alzheimer’s disease. Neurosci Res Commun 1996; 18: 19-28.
3. Armstrong RA. β-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord 1998; 9: 227-238.
4. Armstrong RA. Diffuse β-amyloid (Aβ) deposits and neurons: in situ secretion or diffusion of Aβ. Alz Rep 2001; 3: 289-294.
5. Armstrong RA. Classic β-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic Alzheimer’s disease. Curr Neurovasc Res 2006; 3: 289-294.
6. Armstrong RA. Density and spatial pattern of β-amyloid (Aβ) deposits in corticobasal degeneration. Folia Neuropathol 2011; 49: 14-20.

7. Armstrong RA. When to use the Bonferroni correction. Ophthal Physiol Opt 2014; 34: 502-508.
8. Armstrong RA. Laminar distribution of β-amyloid (Aβ) peptide deposits in frontal lobe in familial and sporadic Alzheimer’s disease. Folia Neuropathol 2015; 53: 15-23.
9. Armstrong RA. Evidence from spatial pattern analysis for the anatomical spread of β-amyloid in Parkinson’s disease dementia. Folia Neuropathol 2017; 55: 23-30.
10. Armstrong RA. A comparison of the spatial patterns of β-amyloid (Aβ) deposits in five neurodegenerative disorders. Folia Neuropathol 2018; 56: 284-292.
11. Armstrong RA. Risk factors for Alzheimer’s disease. Folia Neuropathol 2019; 57: 87-105.
12. Armstrong RA, Smith CUM. β-amyloid (Aβ) deposition in the medial temporal lobe in Down’s syndrome: effects of brain region and patient age. Neurobiol Dis 1995; 1: 139-144.
13. Armstrong RA, Cairns NJ, Lantos PL. Laminar distribution of cortical Lewy bodies and neurofibrillary tangles in dementia with Lewy bodies. Neurosci Res Comm 1997; 21: 145-152.
14. Armstrong RA, Cairns NJ, Lantos PL. Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: Comparison with non-demented cases and Alzheimer’s disease. Dement Geriatr Cogn Disord 2000; 11: 187-192.
15. Armstrong RA, Cairns NJ, Lantos PL. Laminar distribution of ballooned neurons and tau-positive neurons in corticobasal degeneration. Neurosci Res Comm 2000; 27: 85-93.
16. Armstrong RA, Lantos PL, Cairns NJ. The spatial pattern of prion protein deposits in Creutzfeldt-Jakob disease: Comparison with β-amyloid deposits in Alzheimer’s disease. Neurosci Lett 2001; 298: 53-56.
17. Armstrong RA, McKee AC, Stein TD, Alvarez VE, Cairns NJ. A quantitative study of tau pathology in 11 cases of chronic traumatic encephalopathy. Neuropathol Appl Neurobiol 2016; 43: 154-166.
18. Armstrong RA, McKee AC, Alvarez VE, Cairns NJ. Clustering of tau-immunoreactive pathology in chronic traumatic encephalopathy. J Neurol Transm 2016b; 124: 185-192.
19. Armstrong RA, McKee AC, Stein TD, Alvarez VE, Cairns NJ. Cortical degeneration in chronic traumatic encephalopathy and Alzheimer’s disease neuropathologic change. Neurol Sci 2019; 40: 529-533.
20. Bahmanyar S, Higgins GA, Goldgaber D. Localization of amyloid β protein messenger RNA in brains from patients with Alzheimer’s disease. Science 1987; 237: 77-80.
21. Bell MA and Ball MJ. Neuritic plaques and vessels of visual cortex in aging and Alzheimer’s dementia. Neurobiol Aging 1990; 11: 359-370.
22. Braak H, Braak E, Kalus P. Alzheimer’s disease: areal and laminar pathology in the occipital isocortex. Acta Neuropathol 2019; 77: 494-506.
23. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
24. De Lacoste M, White CL. The role of cortical connectivity in Alzheimer’s disease pathogenesis: a review and model system. Neurobiol Aging 1993; 14: 1-16.
25. Delaere P, Duyckaerts C, Brion JP, Poulain V, Hauw JJ. Tau, paired helical filament and amyloid in the neocortex: A morphometric study of 15 cases with graded intellectual status in aging.
and senile dementia of the Alzheimer type. Acta Neuropathol 1989; 77: 645-653.

26. Delaere P, Duyskaerts C, He Y, Piette F, Hauw JJ. Subtypes and differential distribution of Aβ deposition in Alzheimer’s disease: Relationship with the intellectual status of 26 cases. Acta Neuropathol 1991; 81: 328-335.

27. Dickson DW, Bergeron C, Chin SS, Duyskaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan, I. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61: 935-946.

28. Duyskaerts C, Hauw J, Bastenare F, Piette F, Poulaun C, Rainsard V, Jawoy-Agid F, Berthaux P. Laminar distribution of neocortical senile plaques in senile dementia of the Alzheimer type. Acta Neuropathol 1986; 70: 249-256.

29. Eggersperger R, Weggan S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA. Reverse relationship between β-amyloid precursor protein and β-amyloid plaques in Down’s syndrome versus sporadic/familial Alzheimer’s disease. Acta Neuropathol 1999; 97: 113-118.

30. Geddes J, Vowles G, Nicoll J, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive brain injury. Acta Neuropathol 1999; 98: 171-178.

31. Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1311-1315.

32. Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, Crowther RA. From genetics to pathology: tau and α-synuclein assemblies in neurodegenerative diseases. Phil Trans Roy Soc (Lond) B. Biol Sci 2001; 356: 213-227.

33. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33: 317-325.

34. Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAJ, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathological regional analysis and comparison with Alzheimer’s disease. Arch Neurol 1995; 52: 379-391.

35. Greenberg BD. The COOH-terminus of the Alzheimer amyloid Aβ peptide: Differences in length influence the process of amyloid deposition in Alzheimer brain, and tell us something about relationships among parenchymal and vessel-associated amyloid deposits. Amyloid 1995; 21: 195-203.

36. Hamilton RL, Bouser R. Alzheimer’s disease pathology in amyotrophic lateral sclerosis. Acta Neuropathol 2004; 107: 515-522.

37. Hardy JA, Higgins GA. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992; 256: 184-185.

38. Hof PR, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer’s disease: 11 primary and secondary visual cortex. J Comp Neurol 1990; 301: 55-64.

39. Hof PR, Bouras C, Peri DR. Sparks DJ, Mehta N, Morrison JH. Age-related distribution of neuropathological changes in the cerebral cortex of patients with Down’s syndrome: quantitative analysis and comparison with Alzheimer’s disease. Arch Neurol 2000; 57: 81-98.

40. Hof PR, Raulo RF, Webster E. Amyloid, dementia and Alzheimer’s disease. Curr Opin in Neurol Neuropsych 1992; 5: 88-93.

41. Hof PR, West HL, Rebeck GW, bulkley RN, Mantegna M, Ukleya M, Harlin S, Stanley HE. Quantitative analysis of senile plaques in Alzheimer’s disease: observation of log-normal size distributions associated with apolipoprotein E genotype and trisomy 21 (Down’s syndrome). Proc Natl Acad Sci USA 1995; 92: 3586-3590.

42. Hof PR, Hageman GS, Beach TG, Bigio EH, Cairns NJ, Carrella MC, Dickson DW, Duyskaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012; 8: 1-13.

43. Hyman BT. The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurosci 2013; 9: 222-230.

44. Khatchaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol 1985; 42: 1097-1105.

45. Kimpton PT, Montenegro PH, Solomon TM, McKee AC. Chronic traumatic encephalopathy: A neurodegenerative consequence of repetitive brain injury. Sem Neurol 2015; 35: 20-28.

46. Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Ann Rev Neurosci 2001; 24: 1121-1159.

47. Mann DMA, Younis N, Jones D, Stoddart RW. The time course of pathological events in Down’s syndrome with particular reference to the involvement of microglial cells and deposits of β/A4. Neurodegen 1999; 1: 201-215.

48. Maroon JC, Winkelman R, Bost J, Amos A, Mathyssek C, Miele V. Chronic traumatic encephalopathy in contact sports: A systematic review of all reported pathological cases. PLoS One 2015; 10: e0117338.

49. McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DJ, Kibulius CA, Corrigan KA, Jacobs MA, Martin BR, Abrahm CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136: 43-64.

50. McKee AC, Stein TD, McKean PT, Alvarez VE. The neuropathology of chronic traumatic encephalopathy. Brain Pathol 2015; 25: 350-364.

51. McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CQ, Litvan, I, Peri DR, Stein TD, Vonsattel JP, Stewart W, Tripodi V, Cyrie JF, Bienick KF, Dams-O’Connor K, Alvarez VF, Gordon WA, The TBI/CTE group. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 2016; 131: 75-86.
Cortical laminar distributions of Aβ deposits

diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.

55. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The consortium to establish a registry of the neuropathological assessment of Alzheimer’s disease (CERAD). II. Standardization of the neuropathological assessment of Alzheimer’s disease. Neurology 1991; 41: 479-486.

56. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duuyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on Aging; Alzheimer’s Association. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012; 23: 1-11.

57. Motte J, Williams RS. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol 1989; 77: 535-546.

58. Rafałowska I, Barcikowska M, Wen GY, Wisniewski HM. Laminar distribution of neuritic plaques in normal aging, Alzheimer’s disease and Down’s syndrome. Acta Neuropathol 1988; 77: 21-25.

59. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: Neuropathological and clinical heterogeneity. Neurology 1990; 48: 959-969.

60. Selkoe DJ. Deciphering Alzheimer’s disease: the amyloid precursor protein yields further new clues. Science 1990; 248: 1058-1060.

61. Sheng JG, Griffin VST, Royston MC, Mrak RE. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer’s disease. Neuropath Appl Neurobiol 1998; 24: 278-283.

62. Shetty AK, Mishra V, Kodali M, Hattiangady B. Blood brain barrier dysfunction and delayed neurological deficits in mild traumatic brain injury induced by blast shock waves. Front Cell Neurosci 2014; 8: 232.

63. Snedecor GW, Cochran WG. Statistical methods. Iowa State University Press, Ames, Iowa USA 1980.

64. Spargo E, Luthert PJ, Anderton BH, Bruce M, Smith D, Lantos PL. Antibodies raised against different proteins of A4 protein identify a subset of plaques in Down’s syndrome. Neurosci Lett 1990; 115: 345-350.

65. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 1998; 251: 205-208.

66. Stein TD, Montenegro PH, Alvarez VE, Xia W, Cray IF, Tripodis Y, Daneshwar DH, Mez J, Solomon T, Meng G, Kublius CA, Comi er KA, Meng KA, Bocock K, Kiernan P, Murphy L, Nowinski CK, Martin B, Dixon D, Stern RA, Cantu RC, Kowall NW, McKee AC. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol 2015; 130: 21-34.

67. Steiner JA, Angot E, Brunden P. A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ 2011; 18: 1425-1433.

68. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, Nieuwstraten P. The NINCDS-ADRDA work group cri-